NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 5.6 %

NBY stock opened at $0.57 on Friday. The company has a 50-day simple moving average of $0.63 and a 200 day simple moving average of $0.99. The company has a market capitalization of $2.80 million, a P/E ratio of -0.01 and a beta of 0.69. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.